hCAI/II-IN-4_product_DataBase

Bioactivity	hCAI/II-IN-4 (compound 6d) is a potent dual hCA I/II inhibitor with Ki values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. hCAI/II-IN-4 has anti-hypoxia activities and low toxicity. hCAI/II-IN-4 can be used for acute mountain sickness (AMS) research[1].
Target	Ki:16.95 nM (hCA I)、15.22 nM (hCA II) and 27.04 nM (hCA Ⅸ)
Invitro	hCAI/II-IN-4 (compound 6d) (5-200μM; 48 hours) has no apparent cytotoxicity in HEK293 cells[1]. Cell Cytotoxicity Assay[1] Cell Line:
In Vivo	hCAI/II-IN-4 (compound 6d) (400-2000 mg/kg; p.o.; Male BLAB/c mice of hypoxia) has no apparent toxic effect in vivo[1]. Animal Model:
Name	hCAI/II-IN-4
CAS	2480284-01-1
Formula	C15H15N3O5S2
Molar Mass	381.43
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Yang C, et al. N-Quinary heterocycle-4-sulphamoylbenzamides exert anti-hypoxic effects as dual inhibitors of carbonic anhydrases I/II. Bioorg Chem. 2020 Jul;100:103931.

PeptideDB